Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.
作者： Anna S Levin , Carlos E Levy , A Edison I Manrique , Eduardo AS Medeiros , Silvia F Costa
DOI: 10.1016/S0924-8579(02)00276-5
关键词:
摘要: Forty consecutive patients with nosomial infections caused by multidrug-resistant Acinetobacter baumannii were treated intravenous ampicillin/sulbactam. The primary bloodstream (32.5%), pneumonia (30%), urinary tract (15%), peritonitis (7.5%), surgical site meningitis (5%) and sinusitis (2.5%). Most severe underlying conditions (median APACHE II score: 14.5) 72.5% occurred in the ICU. Twenty-seven (67.5%) improved/cured, seven (17.5%) failures six (15%) considered to have an indeterminate outcome because died within first 48 h of treatment. Two cases did not respond. median daily dose ampicillin/sulbactam was 6 g/3 g received 12 g/6 g. No adverse effects observed. This study indicates that may be a good safe therapeutic option treat nosocomial multi-drug resistant A. baumannii.
elsevier.com
sci-hub.se 参考文章(26)
X. Corbella, J. Ariza, C. Ardanuy, M. Vuelta, F. Tubau, M. Sora, M. Pujol, F. Gudiol, Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy. ,vol. 42, pp. 793- 802 ,(1998) , 10.1093/JAC/42.6.793
J. M. Cisneros, M. J. Reyes, J. Pachon, B. Becerril, F. J. Caballero, J. L. Garcia Garmendia, C. Ortiz, A. R. Cobacho, Bacteremia Due to Acinetobacter baumannii: Epidemiology, Clinical Findings, and Prognostic Features Clinical Infectious Diseases. ,vol. 22, pp. 1026- 1032 ,(1996) , 10.1093/CLINIDS/22.6.1026
ROBERT H. K. ENG, SHARON M. SMITH, CHARLES E. CHERUBIN, β-Lactamase inhibitors and Acinetobacter spp. Journal of Antimicrobial Chemotherapy. ,vol. 26, pp. 449- 451 ,(1990) , 10.1093/JAC/26.3.449
W H Traub, M Spohr, Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrobial Agents and Chemotherapy. ,vol. 33, pp. 1617- 1619 ,(1989) , 10.1128/AAC.33.9.1617
M. E. Jimenez-Mejias, J. Pachon, B. Becerril, J. Palomino-Nicas, A. Rodriguez-Cobacho, M. Revuelta, Treatment of Multidrug-Resistant Acinetobacter baumannii Meningitis with Ampicillin/Sulbactam Clinical Infectious Diseases. ,vol. 24, pp. 932- 935 ,(1997) , 10.1093/CLINIDS/24.5.932
E.S Go, C Urban, J Burns, N Mariano, K Mosinka-Snipas, J.J Rahal, B Kreiswirth, W Eisner, Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam The Lancet. ,vol. 344, pp. 1329- 1332 ,(1994) , 10.1016/S0140-6736(94)90694-7
Tara K. Jellison, Peggy S. McKinnon, Michael J. Rybak, Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy. ,vol. 21, pp. 142- 148 ,(2001) , 10.1592/PHCO.21.2.142.34114
Peter Safar, Ake Grenvik, Critical Care Medicine : Organizing and Staffing Intensive Care Units Chest. ,vol. 59, pp. 535- 547 ,(1971) , 10.1378/CHEST.59.5.535
George Foulds, Pharmacokinetics of Sulbactam/Ampicillin in Humans: A Review Clinical Infectious Diseases. ,vol. 8, ,(1986) , 10.1093/CLINIDS/8.SUPPLEMENT_5.503
B G Kuah, G Kumarasinghe, J Doran, H R Chang, Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrobial Agents and Chemotherapy. ,vol. 38, pp. 2502- 2503 ,(1994) , 10.1128/AAC.38.10.2502